First-generation vaccines were not the promising drugs in the early days of CVD-19. The herd’s immune system also did not save the day.

The long-awaited silver bullet will stop the pandemic – pan-coronavirus vaccine – and could it be?

The answer is complex.

“Pan-coronavirus vaccine needs star next to it” Dr. Stuart RayAccording to the Vice President of Medicine Information and Analysis at the Johns Hopkins Medical Center Luck.

Such a vaccine can withstand everything Coronavirus, Named after their magnifying glass. Or it could focus on Covidy-19 and countless differences. Or he may be able to cope. Four long-lived coronavirus It travels like a flu – or any combination.

A.D. It can protect against cholera and MR (Middle East Respiratory Syndrome), which appeared in 2002 and killed hundreds of people, and SARS, which occurred in 2012 and killed hundreds of people.

In addition to summarizing the current cholera epidemic, it may be able to suppress the following as soon as it starts.

“Corona virus spreads to human populations,” he said. Dr. Duwan Wesman, Professor at Harvard Medical School and chief investigator in the Department of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital. He is leading a team of researchers working on the pan-coronavirus vaccine with funding from the US National Institutes of Health.

“I do not know when [the next will]. Probably not in our lives. But maybe sometime. Is there a way to develop a vaccine for SARS-CoV-3?

No matter what type of vaccine is used, it is a good goal. Luck.

But it can stay that way forever: Goal.

“I think we need to be proactive in planning for pan-coronavirus vaccination, but it will not be an easy task,” Walker warned. “There is no clear future.”

Ongoing – and future years of work

Whatever the goal — in heaven — there is no shortage of work to accomplish. Global Coronavirus vaccine is a major research priority for nonprofits, government agencies and vaccinators April Article In Nature.

One of the components in the version under construction is: ModernDuke University and a host of biotech companies.

Clinical trials are underway for trials American Army And CaltechDr. Amesh Adalja, senior professor at the Johns Hopkins Health Center, said. Luck.

Such a vaccine could be used as a “silver bullet”, “This is how you get rid of this threat – not just SARS-CoV-2, but all coronavirus.” And 30% of common colds are a good thing.

But he says that these things will take time. A good example is the flu vaccine.

“People have been working on it for some time, but we still don’t have the flu vaccine,” he said. “There are some versions of the international flu vaccine in clinical trials but it is not thought to be effective and does not last with several seasons of influenza.”

Other: HIV.

“We’ve been making vaccines for some pathogens like HIV for the past decade,” Wesman said. “Some scientists used to think decades ago, ‘Buffalo, we only have a few years left before we get vaccinated against HIV,’ but decades later, we know we have a lot to learn about how to do it. ”

“But we have learned a lot from other pathogens,” Wesman said.

“We don’t understand our immune system as much as we should, to sit down and design the best vaccine,” he said.

To make the universal cholera vaccine available to the public, it will require additional research, animal studies and basic human studies, all of which can take years. Dr. Dan BaroqueProfessor of Medicine at Harvard Medical School and Director of the Center for Virology and Vaccination Research – said Luck.

And the process is not at the same time as the speed of the first covine vaccines, ”Adalja said.

“It may take some time before the pan-coronavirus vaccine is available to the general public,” Baruch said. I don’t think anyone will go this fall to get this on CVS.

Promising, but invincible

Experts warn that even if a global coronavirus vaccine is available, bullets may be invulnerable.

Although the pan-coronavirus vaccine has the potential to “stop the epidemic,” at least to prevent serious illness and death, he said the success is enough to catch up with people around the world. Dr. Daniel CuritzcusHead of Infectious Diseases at Brigigman and Women’s Hospital and Professor of Medicine at Harvard Medical School.

Otherwise, the virus could learn to escape the international covand vaccine.

“This is certainly possible,” says Curitzx.

“As long as the virus continues to spread in large numbers, there is a chance that the virus will continue to adapt,” he added. Alternatives to pan-corona vaccine mutations can re-emerge in infected people.

There are two possible goals for Ray vaccines: to prevent infection in general or to prevent serious illness and disruption, as current covine vaccines do.

Pan-coronavirus vaccine can prevent serious illness and discontinuation of all CV-19 variants and subtypes, which theoretically eliminates the need for incentives.

But such a vaccine could still allow the spread of the infection, experts warn, as existing vaccines do.

“If we develop a vaccine that is as broad as possible, we have to give up some energy,” said Wesman.

Ray warns that the concept of pan-coronavirus vaccine may be a good idea to make it easier to realize – but hopes that such a development “will certainly hit the sweet spot of protection and sustainability.”

“One of the things that keeps us awake at night is that if we do things that don’t control the transmission, it will continue to evolve and create a gap in our device,” he said.

Federal officials say up to 23 million survivors of the disease could be affected by a long-term covide.

Studies show that “even mild to moderate covide can have long-term consequences for heart and mental health outcomes,” says Ray. “We can prevent severe disease in the first two weeks but we see damage accumulated by relatively minor infections.”

This story was initially featured

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *